The Australian Pharmaceutical Benefits Scheme data collection: a practical guide for researchers

Background The Pharmaceutical Benefits Scheme (PBS) is Australia’s national drug subsidy program. This paper provides a practical guide to researchers using PBS data to examine prescribed medicine use. Findings Excerpts of the PBS data collection are available in a variety of formats. We describe the core components of four publicly available extracts (the Australian Statistics on Medicines, PBS statistics online, section 85 extract, under co-payment extract). We also detail common analytical challenges and key issues regarding the interpretation of utilisation using the PBS collection and its various extracts. Conclusions Research using routinely collected data is increasing internationally. PBS data are a valuable resource for Australian pharmacoepidemiological and pharmaceutical policy research. A detailed knowledge of the PBS, the nuances of data capture, and the extracts available for research purposes are necessary to ensure robust methodology, interpretation, and translation of study findings into policy and practice.


Findings
In recent decades the discipline of pharmacoepidemiology has experienced exponential growth, both in Australia [1] and internationally [2][3][4]. This growth has been driven, at least in part, by the increasing availability of routinely collected dispensing databases and increased access to data linkage of dispensing claims and other health data collections. In addition, there has been recognition of the limitations of randomised controlled trials (RCTs) to inform post-market medicine use, including their short duration, small sample size, and non-representative patient populations [5]. Studies using routinely collected databases overcome many of these difficulties, complementing findings from RCTs and offering valuable insights into the real-world use, safety, and effectiveness of medicines [2].
There are a wealth of databases available for pharmacoepidemiological research, and while there are commonalities across health jurisdictions, each dataset has its own idiosyncrasies with respect to analysis and interpretation. Researchers must be familiar with the limitations and features of their chosen dataset. The purpose of this paper is to provide a practical guide for researchers using Australia's Pharmaceutical Benefits Scheme (PBS) dispensing data. Specifically, we will set the scene by describing the PBS, the Australian Government's subsidised prescription medicines program. We will then detail the specifics of the PBS data collection and the PBS data extracts available to examine trends in prescribed medicine use. Finally, we will consider some of the factors affecting the interpretation of prescribed medicine use based on PBS claims.

Background: the Pharmaceutical Benefits Scheme (PBS) and Repatriation Pharmaceutical Benefits Scheme (RPBS)
Australia has universal health care arrangements entitling all citizens and permanent residents to a range of subsidised healthcare services. Prescription medicines are subsidised under two Commonwealth schemes: the PBS and the Repatriation Pharmaceutical Benefits Scheme (RPBS). The PBS subsidises prescribed medicines for Australian residents and eligible foreign visitors (i.e. those with reciprocal health care agreements with Australia). The RPBS, available to eligible war veterans and their families, comprises all PBS-listed medicines and additional subsidised pharmaceutical items [6].
The Australian Government reimburses community pharmacies and private hospitals for PBS-listed medicines, subsidising approximately 75 % of prescribed medicine use in Australia [7]. Prescriptions dispensed to public hospital inpatients have not traditionally been PBS-subsidised; however, the Australian Government has individual agreements with most Australian states and territories (except New South Wales and the Australian Capital Territory) under the Public Hospital Pharmaceutical Reforms, enabling participating hospitals to provide discharging patients and outpatients with PBSsubsidised medicines [8].

Schedule of Pharmaceutical Benefits
The PBS underpins Australia's National Medicines Policy, which is concerned with providing access to safe, effective, and affordable medicines, and ensuring their quality use [9]. The PBS is governed by the National Health Act 1953 and the National Health (Pharmaceutical Benefits) Regulations 1960 (Cth) Act, and is administered by the Department of Human Services (DHS; formerly known as Medicare Australia and the Health Insurance Commission) under the Health Insurance Act 1973 (Cth).
A medicine is eligible for listing on the PBS or RPBS after it has been registered for use in Australia by the Therapeutic Goods Administration (TGA). To gain listing it must be assessed and recommended by the Pharmaceutical Benefits Advisory Committee (PBAC), an independent expert body appointed by the Australian Government. In making its recommendation, PBAC considers the medicine's clinical place, effectiveness, safety, cost, and cost-effectiveness compared to currently available treatments [10]. After a positive recommendation from PBAC, the Minister for Health authorises the medicine to be listed on the Schedule of Pharmaceutical Benefits.

PBS benefit categories
Medicines are PBS-listed according to one of three benefit categories [11]: • Unrestricted benefits Medicines available for general use without limits on the subsidised indication for prescribing. • Restricted benefits Medicines available for the treatment of certain indications or patient groups. If the medicine is prescribed outside the PBS-specified indication, prescribers are required to write private (unsubsidised) prescriptions. • Authority required benefits An authority prescription is required for certain restricted medicines and for cases where a higher dose or quantity of the medicine is required than the maximum approved on the PBS. Authority benefits fall into two categories: (a) Authority required prescriptions, which require the prescriber to obtain written or telephone approval from DHS or Department of Veterans' Affairs (DVA) before dispensing is permitted; and (b) Authority required (STREAMLINED) prescriptions, which do not require prior approval from DHS or DVA, but a streamlined authority code must be provided on the prescription [12].

Sections of the Schedule of Pharmaceutical Benefits
Medicines listed on the Schedule of Pharmaceutical Benefits are also classified into sections based on the National Health Act 1953 [6,13,14].
• Section 85 (s85) of the Act pertains to medicines available under the standard arrangements established for medicine subsidy. S85 or general medicines comprise the majority of prescriptions supplied under the PBS and RPBS. • Section 100 (s100) refers to medicines subsidised under special arrangements. For example, s100 medicines may be restricted to supply through a hospital with specified specialist facilities [15]. This section includes many specialty, high cost medicines, such as chemotherapy and chronic illness agents, as well as medicine programs including the Botulinum Program, Growth Hormone Program, In Vitro Fertilisation/Gamete Intrafallopian Transfer Program, and the Opiate Dependence Treatment Program [6,14]. Special arrangements also exist for the supply of PBS medicines to clients of eligible Aboriginal Health Services in remote areas of Australia [16].

Patient categories Beneficiary status
To ensure affordability of medicines for all Australians, the level of subsidy under the PBS depends on the patient's beneficiary status. Concessional status was established for individuals who are eligible to receive government entitlements, including pensioners, low-income earners, repatriates, and Indigenous Australians living with or at risk of chronic illness (the latter under the Closing the Gap co-payment measure) [17,18]. Eligible veterans and their dependents holding a DVA health card are also entitled to medicines and additional pharmaceutical items at concessional rates under the RPBS [19]. These patients have a low co-payment threshold. All other individuals are considered general beneficiaries and have a higher co-payment threshold. As of 1 January 2015, the maximum co-payment was AUD$6.10 for concessional beneficiaries and AUD$37.70 for general beneficiaries [20]. For medicines costing more than the relevant beneficiary co-payment (i.e. over co-payment), additional costs are paid by the Commonwealth. Medicines costing less than the relevant co-payment (i.e. under co-payment) are not subsidised, but paid in full by the patient. Currently all PBS-listed medicines are priced above the concessional beneficiary co-payment but may be priced above or below the general beneficiary co-payment.

PBS Safety Net
The PBS Safety Net was established to provide financial assistance to individuals and their families spending large amounts on medicines in a calendar year. Once a family collectively spends over the threshold amount (as of 1 January 2015, AUD $1453.90 for general beneficiaries and AUD $366.00 for concessional beneficiaries), the subsequent cost of dispensings for all family members are reduced such that general beneficiaries pay the concessional co-payment rate, and concessional beneficiaries have no co-payments so they receive medicines free of charge [20]. As the reduced cost of dispensings can encourage patients to obtain additional quantities of medicines before they are needed, the Government introduced the Safety Net 20 day rule on 1 January 2006 to encourage responsible use of the PBS. The rule means that, for selected PBS-subsidised medicines used for long-term therapy, a repeat supply of the same medicine within 20 days does not count towards reaching the PBS Safety Net threshold. Moreover, these medicines will not be supplied at the reduced price if the threshold has already been reached [21].

Doctor/prescriber bag (emergency drug supply)
Certain PBS medicines are provided to doctors to treat patients in emergencies [22]. These medicines are free for the doctor and patient as they are completely subsidised by the Commonwealth.

The PBS/RPBS data collection
PBS/RPBS dispensing claims submitted for payment of a government subsidy are processed by DHS and provided to the Department of Health (DoH) and DVA (for their clients only) for monitoring, evaluation, and health service planning.
As of 1 April 2012, DHS also processed dispensing records for under co-payment medicines. The collection of under co-payment records was agreed to under the Fifth Community Pharmacy Agreement and legislated under the National Health Amendment (PBS) Act 2010 [23]. As a result, under co-payment dispensing data are now recorded in the PBS data collection.
When a PBS/RPBS medicine is dispensed, the administering pharmacy or hospital provides DHS with data pertaining to the prescription dispensed, identity of the patient, prescribing doctor, and supplying pharmacy. This information forms the basis of the PBS collection. Identifying information about the patient, doctor and pharmacy (such as names and addresses) is not available to researchers or in the public domain. Moreover, policies such as the suppression of cell counts in aggregated public domain data also apply to protect patient privacy. A summary of key variables provided in the PBS collection is provided in Table 1.
Details of medicine dispensings requiring written or telephone authorisation are stored in a separate Authority Approvals database by DHS. This database records prescription details for authority required medicines, including patient identifiers, PBS item code, the date on which authority approval was obtained, prescriber identifiers, and the authority restriction number, which provides the reason, or indication, for dispensing as declared by the prescribing physician. However, the validity of authority codes (including streamlined) for inferring patient diagnosis is uncertain; this relies on the doctor or pharmacist selecting the correct code.

PBS/RPBS data extracts
PBS/RPBS data are available in a variety of formats. Aggregated (de-identified) data are available online from DHS [24] or DoH [25] in fixed or interactive forms, while more detailed, customised reports in aggregated or unitrecord formats can be requested from DHS, DoH, or DVA.

Variable Definition
Medicine details ATC code Internationally accepted, WHO-defined codes a that classify medicines over five levels, starting broadly with the anatomical site of action (e.g. nervous system) and ending specifically with the chemical substance (e.g. oxycodone) [44] PBS item code Pharmaceutical Benefits Scheme defined codes that provide medicine details at the product level, including generic name, form, strength, administration route, quantity per unit (pack size), and approved indication, where applicable  [24]. The customised reports, available from 1992, can be downloaded based on individual PBS item codes, or grouped by ATC classifications (e.g. alimentary tract and metabolism) or patient category. Reports can also be formatted according to the state/territory location of the dispensing pharmacy, and according to month, calendar year or financial year of processing. Importantly, the reports do not include data on under co-payment or private prescriptions and there is limited capture of s100 medicines [27]. Data on s100 highly specialised drugs dispensed in public hospitals are not available prior to July 2013; a transition to online claiming in public hospitals enabled collection of data at the level of the individual prescription from this date [28].
Reports are based on date of processing by DHS, not the date of supply.
Section 85 extract DoH has developed an online, downloadable extract of s85 dispensing records [25]. Reports are available by month of processing (annually from 2008/2009, with monthly updates), or month of supply (single extract from July 2009, excluding most recent 6 months). Both reports aggregate volume and costs according to patient category. These data also include under co-payment medicines from 1 July 2012 and Closing the Gap under co-payment data from 1 July 2010. Institute of Health and Welfare using monthly data from state and territory registries of births, deaths and marriages, and is matched to PBS/RPBS dispensing records [30]. All other data extracts require specific approval.

PBS/RPBS under co-payment extract
The main features of the data extracts in this section are described in Table 2.

Factors affecting the interpretation of prescribed medicine use based on PBS/RPBS claims
This section describes some of the common challenges encountered when using the PBS/RPBS database and its various extracts to obtain utilisation estimates.

Seasonality
PBS data are subject to seasonality due to the effect of the Safety Net (Fig. 1). As previously mentioned, when a family spends over a specified amount on PBS medicines in one calendar year (i.e. exceeds the Safety Net threshold), the cost of all subsequent PBS medicines are reduced to the concessional rate for general beneficiaries and are free for concessional beneficiaries. This reduced medicine price on reaching the Safety Net can lead to a phenomenon known as stockpiling: Safety Net entitlements result in some patients obtaining extra quantities of their medicines toward the end of the year, stockpiling for the new year when they revert back to paying standard prices. This results in increased rates of dispensing of the medicine toward the end of the year followed by a trough at the start of the next year. Despite attempts to reduce this phenomenon through the introduction of the Safety Net 20 day rule on 1 January 2006, stockpiling continues to result in pronounced seasonality in utilisation data based on date of supply.

Date of supply vs. date of processing
Each dispensing claim records the date a medicine is supplied to a patient by the dispensing pharmacy or the date the dispensing pharmacy's claim for reimbursement is processed by DHS. Some of the data extracts include both of these variables while others include only one. For example, ASM reports are based around date of supply, PBS Statistics online use date of processing, and Section 85 online extracts are available by either date. There is often a discrepancy in utilisation measures based on date of supply versus those based on date of processing as the processing of the claim occurs some time after the prescription is dispensed and the interval of time between dispensing and processing is variable [25]. As such, caution must be employed when using data based  Figure 2 depicts the discrepancy between utilisation estimates based on date of supply compared to date of processing for all s85 PBS-subsidised medicines. Troughs in utilisation according to date of processing can be seen around late 2011 and late 2013, indicating delays in the processing of claims by DHS. The 2011 trough is followed by compensatory peaks, indicating a period of increased processing. Note that the data by date of supply show seasonal fluctuations as mentioned above. Seasonal fluctuations are less apparent in date of processing graphs due to the variable delay between dispensing and processing.
The risks of using date of processing data are well demonstrated by a recent example. In October 2013, the Australian Broadcasting Corporation's Catalyst program aired a two part series questioning the link between high cholesterol levels and heart disease and suggested that the benefit of statins for preventing cardiovascular disease had been exaggerated. Much public debate followed the program. In May 2014, Australian Doctor published an article based on PBS statistics online data, reporting that there had been no change in statin dispensing for up to 3 months after the program aired [31]. However, our interrupted time series analysis using date of supply showed that there was an immediate and sustained 2.6 % reduction (equating to 500,000 fewer prescriptions) in statin dispensing persisting up to 8 months after the program aired [32].
One caveat concerning use of date of supply data is that dispensing records are not available in the dataset until the claim has been processed by DHS. Due to the variable delay in processing, this can result in incomplete ascertainment of claims dispensed on a given date for a number of months. It is therefore advisable to truncate the observation end date by at least 3 months, and preferably 6 months, to avoid under-reporting of utilisation. Indeed, the Section 85 Date of Supply report does not contain data for the most recent 6 months to ensure that   Fig. 1 The seasonality effect of dispensing records. Monthly dispensings of proton pump inhibitors to concessional beneficiaries, January 2010 to January 2014. Pharmaceutical Benefits Scheme and Repatriation Pharmaceutical Benefits Scheme Section 85 Supply data, Australian Government Department of Health [25] the data are of a satisfactory level of completion before publication.

Ascertainment and under co-payment medicines capture
As previously mentioned, the PBS database did not capture data on the dispensing of under co-payment medicines until at least April 2012 (July 2012 for Section 85 Date of Supply), thereby under-ascertaining the utilisation of certain medicines prior to this time. As under copayment prescriptions comprised approximately 18 % of medicine use in 2011 [7], this issue significantly impacts utilisation estimates for certain drugs.
To determine if a particular PBS item was underascertained it is necessary to track the time points at which the cost of the medicine fell below the general co-payment threshold in the study period (prior to April 2012). As the co-payment threshold increases yearly and medicine prices change over time, the medicine's price must be compared to the yearly co-payment threshold throughout the period of interest. The inclusion of under co-payment data in 2012 also must be considered when examining utilisation of under co-payment medicines over this period. It should also be noted that while DHS now records all under co-payment dispensing claims, not all of the collections detailed in this document incorporate under co-payment data as part of the extract (see Table 2).
An example of how these issues affect the data is provided in Fig. 3. Oxycodone suppositories (30 mg; PBS item code 2481N) were under co-payment between January 1998 and December 2004. Oxycodone utilisation was under-ascertained in the PBS dataset for the duration of this under co-payment period; only use by concessional beneficiaries or general beneficiaries qualifying for the PBS Safety Net were captured. In December 2004, the price of item 2481N increased from AUD$18.42 to AUD$29.84, exceeding the co-payment threshold of AUD$23.70. This transition to over co-payment resulted in more complete capture of medicine use; PBS-subsidised utilisation increased as a result, and under co-payment utilisation dropped off. As this medicine was above co-payment in 2012, it was not affected by the change in data collection by DHS.
However, the impact of this change on medicine ascertainment can be demonstrated by examining trends in antidepressant utilisation over this period. As many antidepressants are off-patent, there is a high rate of under co-payment utilisation of this class. Accordingly, Fig. 4 demonstrates a sharp increase in antidepressant prescriptions coinciding with the uptake of under co-payment medicines into the dataset.
The capture of under co-payment medicines has implications for analyses using unit-level data. If the medicine of interest is under co-payment for all or part of the study period, restriction of the study population to concessional beneficiaries or DVA clients can ensure more complete ascertainment of medicine use. This is because the concessional co-payment threshold is lower than the cost of any medicine on the PBS. This method has been widely used in Australian studies using unit-level PBS data: of 113 such studies published between 1987 and 2013, 75 % employed a study population comprised of concessional beneficiaries or veterans [1]. As the concessional status of a patient can change over time, inclusion should ideally be further restricted to individuals for whom all dispensed medicines are provided at the concessional rate during the study period. Alternatively, under co-payment use of medicines  [25] requiring written or telephone authority approval can be tracked using the Authority Approvals database (such as use of dexamphetamine and methylphenidate in attention deficit hyperactivity disorder).

Changes to medicine coding: ATC and PBS item code changes
Both PBS item and ATC codes are subject to change and this requires consideration when examining utilisation trends. For example, the antidepressant venlafaxine was listed under the ATC code N06AE06 until 1995, when its code changed to N06AA22. The code was further changed in 1999 to N06AX16 [33]. Similarly, a particular formulation of tobramycin, a systemic antibiotic, had the PBS item code 1356J until December 2005, when the code changed to 8872Y [34]. While the original item code still exists, it no longer refers to this formulation.
It is therefore important to ensure that all relevant historical and current ATC and/or PBS item codes are included in the analysis to avoid errors in utilisation estimates. Defining medicines of interest by ATC codes rather than item codes can help to overcome this problem, as ATC codes capture all current and historical PBS item codes, are less prone to change, and any historical changes in ATC code can be easily determined from the World Health Organisation Collaborating Centre for Drug Statistics Methodology (WHOCC) website [33]. One caveat is that there are occasional differences between the WHOdefined ATC codes and the ATC codes present in the PBS dataset. For example, lithium carbonate is classified as an antipsychotic by WHO (code N05AN01) but as an antidepressant by the PBS (code N06AX) [35]. Changes in PBS item codes are more difficult to track, but are recorded from 2003 in PBS monthly reports [36].  [25] It is also worth noting that a medicine may concurrently have more than one ATC code (when the medicine has multiple indications affecting different body systems) or item code [according to the indication, strength, or prescriber (i.e. medical practitioner, nurse practitioner, or dentist) of a particular formulation]. Therefore, in some cases, the item code may provide a proxy of the indication or reason for prescribing. For example, the antineoplastic bevacizumab is available under item code 10114H for epithelial ovarian, fallopian tube or primary peritoneal cancer, but under 4400N for colorectal cancer. However, other drugs have multiple indications for prescribing combined under a single code (e.g. one item code for the antidepressant paroxetine is used for major depressive disorder, obsessive compulsive disorder, and panic disorder). Additionally, the validity of item codes for inferring patient diagnosis is uncertain. Depending on the research question, the researcher may choose to include all codes or only those referring to a certain indication or prescriber type.

Policy changes
Changes in the medicine reimbursement process can impact data capture and estimates of utilisation. For example, the introduction of the Public Hospital Pharmaceutical Reforms from 2001 increased access to PBSsubsidised medicines by allowing participating public hospitals to provide PBS medicines to patients at discharge and outpatients. These Reforms are governed by individual agreements between each state and territory and the Australian Government. Agreements were initially established in Victoria (September 2001), followed by Queensland (August 2002), Western Australia (2002), Northern Territory (January 2007), South Australia (August 2008) and Tasmania (December 2010), with reforms implemented gradually across each state [37]. New South Wales and the Australian Capital Territory do not participate in the Reforms. Researchers conducting state-by-state comparisons should consider whether the introduction of the Reforms may influence utilisation estimates for the medicines of interest. A variable indicating the type of dispensing pharmacy (hospital, community) can be provided with PBS data by request.
In late 2011 the Pharmaceutical Reforms were varied to enable the introduction of a new scheme governing the subsidy of chemotherapeutic agents, the Revised Arrangements for the Efficient Funding of Chemotherapy measure [37]. These arrangements came into effect in December 2011 for private hospitals and community pharmacies, and April 2012 for public hospitals [38]. S100 medicines dispensed in public hospitals have traditionally been processed in bulk by DHS at the end of each month, and therefore were not recorded as individual-level dispensing claims or included in the dataset. However, the Efficient Funding of Chemotherapy resulted in a shift from bulk to unit-level processing of s100 chemotherapeutic items and increased capture of these medicines in the dataset. As such, an increase in utilisation of s100 medicines dispensed through public hospitals can be observed following the introduction of the scheme. These examples highlight the need to question significant and unexpected changes in the data to determine whether they represent a true change in utilisation or an artefact of the way the data are ascertained.

Measures of utilisation
Medicine use can be quantified in a variety of ways in the PBS dataset, including by number of dispensings or costs. The strength of the medicine and quantity supplied can also be used to calculate DDD/1000 pop/day, a widely used measure of utilisation allowing for standardisation of drug use across countries and different forms of the drug. The DDD metric, established by the WHOCC, is based on the estimated mean daily dose of the drug when used for its main indication in adults [6]. DDD/1000 pop/ day can be calculated for both plain products (which contain only one active ingredient) and combination products (with more than one active ingredient). The DUSC calculates DDD/1000 pop/day for combination products by counting the DDD for each constituent separately [7]; this method contrasts with that used by the WHOCC, who assign DDDs by counting the entire combination as one daily dose [39]. This methodological difference should be considered when making international comparisons of utilisation using DDDs.
Different measures of utilisation may yield differing results, and researchers must determine which measure(s) is most appropriate for their research question and dataset, considering the strengths and limitations of the chosen measure. Prescription-based measures such as 'number of dispensings' do not standardise utilisation across populations, or across different medicine strengths and pack sizes. While DDD/1000 pop/day is useful for standardising population-based measurements, the DDD on which it is based does not necessarily accurately reflect the dose recommended or prescribed. DDD is also limited for quantifying medicines use in children and the elderly, for whom different doses may be used. As with ATC codes, DDDs can change over time; a list of changes can be accessed from WHOCC [40]. Figure 5 demonstrates the differing results obtained when measuring utilisation by number of prescriptions dispensed, DDD/1000 pop/day, or medicine cost to government for the antipsychotic quetiapine; the antidepressant desvenlafaxine; the benzodiazepine diazepam; and the stimulant methylphenidate. Each of these measures have certain strengths and weaknesses. For example, the DDD of quetiapine is 400 mg, which is the average dose for an adult patient diagnosed with psychosis. However, a recent analysis by DUSC revealed that 23 % of patients taking quetiapine are using only the 25 mg strength of the drug, likely for the treatment of non-psychotic disorders such as anxiety and insomnia [41]; DDD/1000 pop/day would therefore likely under-estimate true use. In addition, quetiapine is one of the most costly medicines to the Australian Government [42], and analyses relying solely on cost would over-estimate its utilisation. Assessment of utilisation by number of prescriptions dispensed can also be problematic when comparing between different drugs, strengths and pack sizes. Quetiapine, for example, is usually dispensed in packs of 60 tablets, while desvenlafaxine has a pack size of 28. Use of different measures of utilisation may also impact trends in medicine use. For example, the increase in quetiapine use between 2006 and 2011 is more pronounced when measured by number of prescriptions (232 % increase) than by cost (154 % increase) or DDD/1000 pop/day (123 % increase).

Conclusions
As a result of its universal healthcare arrangements, Australia has access to a whole-of-population dispensing database. The PBS data collection contains records on Australia's 23 million citizens and all PBS, RPBS and under co-payment prescriptions, amounting to approximately 280 million dispensings a year [42]. The database is a valuable resource and has been widely used in both aggregated and unit-level analyses, and in linked and unlinked forms. The current paper has provided an overview of the PBS database and some of the extracts available to researchers, focussing primarily on publicly available, aggregated forms. Clearly these extracts hold great potential as a continuing source of data for pharmacoepidemiological research in Australia. However, the scope of the PBS database extends beyond the extracts and uses described herein.
We recently published a systematic review of all published literature using Australia's PBS dispensing records between 1987 and 2013, identifying 228 studies using PBS data [1]. These studies explored a range of research questions, including trends in drug utilisation; clinical and patient practices around medicine use; drug use and outcomes; evaluations of interventions; and methodological studies undertaken using PBS claims. They also used a variety of PBS data extracts, including the publicly available Section 85 extract and PBS Statistics online, as well as a range of datasets available by request, such as the DUSC dataset, PBS 10 % sample, and DVA RPBS dataset. More than half of the studies combined PBS data with additional health data such as medical service claims-also under the custodianship of DHS-or other routine data such as hospitalisations, fact and cause of death data under the custodianship of Australia's states and territories. Sixty-three studies linked person-level claims with other routine data collections, permitting exploration of drug safety and outcomes and the evaluation of the impact of interventions on utilisation. While the availability of linked data in Australia has traditionally been limited by legislative, privacy and cross-jurisdictional barriers, recent developments in data linkage infrastructure and governance in Australia bring the promise of increased access to population-based linked data for research purposes [43]. These developments, combined with the recent changes in data capture, such as the inclusion of under co-payment data in the PBS dataset from 2012, further strengthen the role of the PBS dataset in pharmacoepidemiological research and place Australia in a powerful position to conduct quality use of medicines research.